Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.07% |
| 2 | Technology | 14.35% |
| 3 | Financials | 11.23% |
| 4 | Consumer Discretionary | 9.93% |
| 5 | Real Estate | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Forward Air
FWRD
$682M
| $2.82M | ﹤0.01% |
47,739
-4,700
| -9% | -$289K |
|
|
SFE
2152
DELISTED
Safeguard Scientifics, Inc.
SFE
| $2.82M | ﹤0.01% |
233,800
+28,400
| +14% | +$333K |
|
2153
NetSol Technologies
NTWK
$49.3M
| $2.82M | ﹤0.01% |
504,013
+14,993
| +3% | +$96.7K |
|
|
CRR
2154
DELISTED
Carbo Ceramics Inc.
CRR
| $2.82M | ﹤0.01% |
2,086,828
+1,191,428
| +133% | +$2.63M |
|
2155
Cumberland Pharmaceuticals
CPIX
$119M
| $2.81M | ﹤0.01% |
441,577
+50,800
| +13% | +$308K |
|
|
SAVE
2156
DELISTED
Spirit Airlines, Inc.
SAVE
| $2.81M | ﹤0.01% |
58,800
-702,200
| -92% | -$35.8M |
|
2157
Kelly Services Class A
KELYA
$566M
| $2.8M | ﹤0.01% |
106,808
-7,500
| -7% | -$179K |
|
|
KDNY
2158
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.79M | ﹤0.01% |
362,440
+130,720
| +56% | +$1.99M |
|
|
VIVS
2159
VivoSim Labs
VIVS
$1.15M
| $2.79M | ﹤0.01% |
22,196
+6,925
| +45% | +$1.31M |
|
2160
Archrock
AROC
$5.84B
| $2.78M | ﹤0.01% |
262,500
+186,500
| +245% | +$1.83M |
|
2161
Ceco Environmental
CECO
$4.44B
| $2.77M | ﹤0.01% |
288,283
+99,510
| +53% | +$852K |
|
2162
Oceaneering
OII
$5.08B
| $2.76M | ﹤0.01% |
135,300
-490,551
| -78% | -$8.68M |
|
|
SNT
2163
Senstar Technologies
SNT
$43.3M
| $2.75M | ﹤0.01% |
547,576
+21,489
| +4% | +$107K |
|
|
SYRS
2164
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.75M | ﹤0.01% |
29,740
+7,690
| +35% | +$535K |
|
|
OIIM
2165
DELISTED
02Micro International
OIIM
| $2.75M | ﹤0.01% |
1,984,560
-28,935
| -1% | -$41.7K |
|
2166
Williams-Sonoma
WSM
$28.9B
| $2.75M | ﹤0.01% |
84,600
-562,600
| -87% | -$16.1M |
|
2167
Telefônica Brasil
VIV
$18.5B
| $2.74M | ﹤0.01% |
210,584
+132,384
| +169% | +$1.61M |
|
|
SSKN
2168
DELISTED
Strata Skin Sciences
SSKN
| $2.74M | ﹤0.01% |
110,012
+6,930
| +7% | +$173K |
|
|
PRCP
2169
DELISTED
Perceptron Inc
PRCP
| $2.73M | ﹤0.01% |
613,130
+13,531
| +2% | +$80.1K |
|
2170
BK Technologies
BKTI
$286M
| $2.72M | ﹤0.01% |
126,340
+1,680
| +1% | +$34.3K |
|
|
NUAN
2171
DELISTED
Nuance Communications, Inc.
NUAN
| $2.71M | ﹤0.01% |
196,183
-506,929
| -72% | -$7.48M |
|
2172
Watsco Inc
WSO
$12.8B
| $2.71M | ﹤0.01% |
16,577
-296,523
| -95% | -$46.6M |
|
2173
Natera
NTRA
$45.5B
| $2.71M | ﹤0.01% |
98,204
-674,200
| -87% | -$14.9M |
|
|
TLRD
2174
DELISTED
Tailored Brands, Inc.
TLRD
| $2.7M | ﹤0.01% |
467,700
-162,200
| -26% | -$1.13M |
|
2175
Intellia Therapeutics
NTLA
$1.66B
| $2.69M | ﹤0.01% |
+164,600
| New | +$2.59M |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.